Showing posts with label pig. Show all posts
Showing posts with label pig. Show all posts

Thursday, 5 June 2014

Scientists Successfully Transplant, Grow Stem Cells in Pigs

New line of pigs do not reject transplants, will allow for future research on stem cell therapies
Thursday, 05 June 2014

One of the biggest challenges for medical researchers studying the effectiveness of stem cell therapies is that transplants or grafts of cells are often rejected by the hosts. This rejection can render experiments useless, making research into potentially life-saving treatments a long and difficult process. Now, researchers at the University of Missouri have shown that a new line of genetically modified pigs will host transplanted cells without the risk of rejection.

R. Michael Roberts is a Curators Professor of   
Animal Science and Biochemistry and a
researcher in the Bond Life Sciences Center. 
Credit: Kyle Spradley. 

"The rejection of transplants and grafts by host bodies is a huge hurdle for medical researchers," said R. Michael Roberts, Curators Professor of Animal Science and Biochemistry and a researcher in the Bond Life Sciences Center.

"By establishing that these pigs will support transplants without the fear of rejection, we can move stem cell therapy research forward at a quicker pace."

In a published study, the team of researchers implanted human pluripotent stem cells in a special line of pigs developed by Randall Prather, an MU Curators Professor of reproductive physiology. Prather specifically created the pigs with immune systems that allow the pigs to accept all transplants or grafts without rejection. Once the scientists implanted the cells, the pigs did not reject the stem cells and the cells thrived. Prather says achieving this success with pigs is notable because pigs are much closer to humans than many other test animals.
Randall Prather is an MU Curators Professor of
reproductive physiology in the College of
Agriculture, Food and Natural Resources. 
Credit: Kyle Spradley.


"Many medical researchers prefer conducting studies with pigs because they are more anatomically similar to humans than other animals, such as mice and rats," Prather said.

"Physically, pigs are much closer to the size and scale of humans than other animals, and they respond to health threats similarly. This means that research in pigs is more likely to have results similar to those in humans for many different tests and treatments."

"Now that we know that human stem cells can thrive in these pigs, a door has been opened for new and exciting research by scientists around the world," Roberts said.

"Hopefully this means that we are one step closer to therapies and treatments for a number of debilitating human diseases."

Contact: Nathan Hurst
.........


For more on stem cells and cloning, go to CellNEWS at

Thursday, 25 June 2009

Pigs' Connective Tissue Cells Converted into Stem Cells

New finding could result in better tests for stem cell therapy, more accurate model Thursday, 25 June 2009 For years, proponents have touted the benefits of embryonic stem cell research, but the potential therapies still face hurdles. Side effects such as tumour development, a lack of an effective and long-term animal model to test new therapies, and genetic incompatibility between the host and donor cells are some of the problems faced by researchers. Now, scientists at the University of Missouri-Columbia have developed the ability to take regular cells from a pig's connective tissues, known as fibroblasts, and transform them into stem cells, eliminating several of these hurdles. The new study appeared in a recent issue of the Proceedings of the National Academy of Sciences (PNAS). "It's important to develop a good, accurate animal model to test these new therapies," said R. Michael Roberts, Curator's Professor of Animal Science and Biochemistry and a researcher in the Bond Life Sciences Center. University of Missouri researchers recently developed the ability to take regular cells from a pig's connective tissues and transform them in stem cells, eliminating several hurdles and some controversy over the use of stem cells. Credit: Christian Basi/University of Missouri."Cures with stem cells are not right around the corner, but the pig could be an excellent model for testing new therapies because it is so similar to humans in many ways." In their research, Roberts; Toshihiko Ezashi, a research assistant professor of animal sciences in the College of Agriculture, Food and Natural Resources and lead author on the study; and Bhanu Telugu, a post-doctoral fellow in animal sciences; cultured fibroblasts from a foetal pig. The scientists then inserted four specific genes into the cells. These genes have the ability to "re-program" the differentiated fibroblasts so that they "believe" they are stem cells, take on many of the properties of stem cells that would normally be derived from embryos, and, like embryonic stem cells, differentiate into many, possibly all, of the more than 250 cell types found in the body of an adult pig. Bhanu Telugu, a post-doctoral fellow in animal sciences in the MU College of Agriculture, Food and Natural Resources and a researcher in the Bond Life Sciences Center, studies stem cells created from connective tissue cells of the pig. Credit: Christian Basi/University of Missouri.Since these "induced pluripotent stem cells" were not derived from embryos and no cloning technique was used to obtain them, the approach eliminates some of the controversy that has accompanied stem cell research in the past. The next step is for Roberts and his team to remove the four genes that reprogrammed the original cells. Then the researchers will determine what needs to be done to direct the new stem cells to develop into specific cell types. "Right now, we researchers have not answered questions concerning how to make stem cells develop into just one type of cell, such as those of liver, kidney or blood cells, rather than a mixture," Roberts said. "Now that we have been able to turn regular cells into stem cells, we need to learn how to make the right type of tissue and then test putting that new tissue back into the animal." Roberts also noted that using the same animal for both the beginning and end of the research would eliminate any host rejection of the transplanted cells once scientists reach the point where they are putting the new tissue back into the animal. Using pigs rather than mice allows researchers to observe any long-term effects of the therapies. Because mice typically have a short life span and differ from humans more than pigs, it is less difficult to predict and/or study long-term effects using pigs, Telugu said. Reference: Derivation of induced pluripotent stem cells from pig somatic cells Toshihiko Ezashi, Bhanu Prakash V. L. Telugu, Andrei P. Alexenko, Shrikesh Sachdev, Sunilima Sinha and R. Michael Roberts PNAS June 18, 2009, doi: 10.1073/pnas.0905284106 ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Artificial Liver for Drug Tests

Artificial Liver for Drug Tests Thursday, 25 June 2009 If you have hay fever, headaches or a cold, it's only a short way to the nearest chemist. The drugs, on the other hand, can take eight to ten years to develop. Until now animal experiments have been an essential step, yet they continue to raise ethical issues. Dr. Johanna Schanz and Prof. Heike Mertsching (f.l.t.r.) work to develop an artificial liver. Credit: Fraunhofer/Dirk Mahler."Our artificial organ systems are aimed at offering an alternative to animal experiments," says Professor Heike Mertsching of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart. "Particularly as humans and animals have different metabolisms. 30 per cent of all side effects come to light in clinical trials." The test system, which Professor Mertsching has developed jointly with Dr. Johanna Schanz, should in future give pharmaceutical companies greater security and shorten the path to new drugs. Both researchers received the "Human-centered Technology" prize for their work. "The special feature, in our liver model for example, is a functioning system of blood vessels," says Dr. Schanz. "This creates a natural environment for cells." Traditional models do not have this, and the cells become inactive. "We don't build artificial blood vessels for this, but use existing ones – from a piece of pig's intestine." All of the pig cells are removed, but the blood vessels are preserved. Human cells are then seeded onto this structure – hepatocytes, which, as in the body, are responsible for transforming and breaking down drugs, and endothelial cells, which act as a barrier between blood and tissue cells. In order to simulate blood and circulation, the researchers put the model into a computer-controlled bioreactor with flexible tube pump, developed by the IGB. This enables the nutrient solution to be fed in and carried away in the same way as in veins and arteries in humans. "The cells were active for up to three weeks," says Dr. Schanz. "This time was sufficient to analyze and evaluate the functions. A longer period of activity is possible, however." The researchers established that the cells work in a similar way to those in the body. They detoxify, break down drugs and build up proteins. These are important pre-conditions for drug tests or transplants, as the effect of a substance can change when transformed or broken down – many drugs are only metabolized into their therapeutic active form in the liver, while others can develop poisonous substances. The researchers have demonstrated the basic possibilities for use of the tissue models – liver, skin, intestine and windpipe. At the moment, the test system is being examined. Within two years it could provide a safer alternative to animal experiments. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Thursday, 4 June 2009

Another Chinese Group Create Pig Embryonic-like Stem Cells

Engineered pig stem cells bridge the mouse-human gap Thursday, 04 June 2009 The discovery that adult skin cells can be 'reprogrammed' to behave like stem cells has been a major scientific boon, providing a way to tap the potential of embryonic stem cells without the associated ethical quandaries. Now, in a study appearing online in JBC, researchers have created a line of such reprogrammed stem cells from adult pigs. As pigs are large animals with a physiology very similar to humans, this work provides a valuable model to study the therapeutic potential of this new "induced pluripotent stem cell" (iPS) technology. iPS cells have already been developed from both mice and humans. Both systems will help researchers answer many biological and genetic questions about these cells, but still leave a gap before clinical applications can begin. These iPS cells cannot be tested on humans before thorough safety and efficacy trials in animal models, but the size, physiology and short lifespan of mice makes them less than ideal for these trials. Duanqing Pei and colleagues, from South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, China, turned to a better pre-clinical model: pigs. These large animals share a remarkably similar biology to humans, as evidenced by their already extensive contributions to medicine, such as using pig insulin to treat diabetes or pig heart valves in transplant surgery. The research group modified the current iPS protocols to successfully generate a line of stem cells from a miniature Tibetan pig (whose smaller size would make breeding and maintenance easier). A biochemical analysis revealed these cells expressed the key proteins that would classify them as 'stem cells' and had the ability to differentiate into many other types of cells. Importantly, these pig iPS cells more closely resembled human stem cells than other animals, confirming their value in pre-clinical studies. The researchers believe porcine iPS technology is an emerging and exciting field that should progress quickly and lead to many applications. Reference: Generation of induced pluripotent stem cell lines from Tibetan miniature pig Miguel Angel Esteban, Jianyong Xu, Jiayin Yang, Meixiu Peng, Dajiang Qin, Wen Li, Zhuoxin Jiang, Jiekai Chen, Kang Deng, Mei Zhong, Jinglei Cai, Liangxue Lai, and Duanqing Pei Journal of Biological Chemistry, April 17, 2009, doi:10.1074/jbc.M109.008938 ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Wednesday, 3 June 2009

Chinese Scientists Create Pig Embryonic-like Stem Cells

Discovery has far-reaching implications for animal and human health Wednesday, 03 June 2009 Scientists have managed to induce cells from pigs to transform into pluripotent stem cells – cells that, like embryonic stem cells, are capable of developing into any type of cell in the body. It is the first time in the world that this has been achieved using somatic cells (cells that are not sperm or egg cells) from any animal with hooves (known as ungulates). The implications of this achievement are far-reaching; the research could open the way to creating models for human genetic diseases, genetically engineering animals for organ transplants for humans, and for developing pigs that are resistant to diseases such as swine flu. The work is the first research paper to be published online today (Wednesday 3 June) in the newly launched Journal of Molecular Cell Biology. Dr Lei Xiao, who led the research, said: "To date, many efforts have been made to establish ungulate pluripotent embryonic stem cells from early embryos without success. This is the first report in the world of the creation of domesticated ungulate pluripotent stem cells. Therefore, it is entirely new, very important and has a number of applications for both human and animal health." Dr Xiao, who heads the stem cell lab at the Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China, and colleagues succeeded in generating induced pluripotent stem cells by using transcription factors to re-programme cells taken from a pig's ear and bone marrow. After the cocktail of reprogramming factors had been introduced into the cells via a virus, the cells changed and developed in the laboratory into colonies of embryonic-like stem cells. Further tests confirmed that they were, in fact, stem cells capable of differentiating into the cell types that make up the three layers in an embryo – endoderm, mesoderm and ectoderm – a quality that all embryonic stem cells have. The information gained from successfully inducing pluripotent stem cells (iPS cells) means that it will be much easier for researchers to go on to develop embryonic stem cells (ES cells) that originate from pig or other ungulate embryos. Dr Xiao said: "Pig pluripotent stem cells would be useful in a number of ways, such as precisely engineering transgenic animals for organ transplantation therapies. The pig species is significantly similar to humans in its form and function, and the organ dimensions are largely similar to human organs. We could use embryonic stem cells or induced stem cells to modify the immune-related genes in the pig to make the pig organ compatible to the human immune system. Then we could use these pigs as organ donors to provide organs for patients that won't trigger an adverse reaction from the patient's own immune system.” "Pig pluripotent stem cell lines could also be used to create models for human genetic diseases. Many human diseases, such as diabetes, are caused by a disorder of gene expression. We could modify the pig gene in the stem cells and generate pigs carrying the same gene disorder so that they would have a similar syndrome to that seen in human patients. Then it would be possible to use the pig model to develop therapies to treat the disease.” "To combat swine flu, for instance, we could make a precise, gene-modified pig to improve the animal's resistance to the disease. We would do this by first, finding a gene that has anti-swine flu activity, or inhibits the proliferation of the swine flu virus; second, we can introduce this gene to the pig via pluripotent stem cells – a process known as gene 'knock-in'. Alternatively, because the swine flu virus needs to bind with a receptor on the cell membrane of the pig to enter the cells and proliferate, we could knock out this receptor in the pig via gene targeting in the pig induced pluripotent stem cell. If the receptor is missing, the virus will not infect the pig." In addition to medical applications for pigs and humans, Dr Xiao said his discovery could be used to improve animal farming, not only by making the pigs healthier, but also by modifying the growth-related genes to change and improve the way the pigs grow. However, Dr Xiao warned that it could take several years before some of the potential medical applications of his research could be used in the clinic. The next stage of his research is to use the pig iPS cells to generate gene-modified pigs that could provide organs for patients, improve the pig species or be used for disease resistance. The modified animals would be either "knock in" pigs where the iPS or ES cells have been used to transfer an additional bit of genetic material (such as a piece of human DNA) into the pig's genome, or "knock out" pigs where the technology is used to prevent a particular gene functioning. Commenting on the study, the journal's editor-in-chief, Professor Dangsheng Li, said: "This research is very exciting because it represents the first rigorous demonstration of the establishment of pluripotent stem cell in ungulate species, which will open up interesting opportunities for creating precise, gene-modified animals for research, therapeutic and agricultural purposes." This release is available in Chinese: 世界首次:中国科学家培育出猪的干细胞 该发现对于动物和人类健康具有深远影响 Reference: Generation of pig induced pluripotent stem cells with a drug-inducible system Journal of Molecular Cell Biology. doi:10.1093/jmcb/jmp003 ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Friday, 29 May 2009

Adult Bone Marrow Stem Cells Injected Into Skeletal Muscle Can Repair Heart Tissue

Adult Bone Marrow Stem Cells Injected Into Skeletal Muscle Can Repair Heart Tissue Friday, 29 May 2009 University at Buffalo researchers have demonstrated for the first time that injecting adult bone marrow stem cells into skeletal muscle can repair cardiac tissue, reversing heart failure. Using an animal model, the researchers showed that this non-invasive procedure increased myocytes, or heart cells, by two-fold and reduced cardiac tissue injury by 60 percent. The therapy also improved function of the left ventricle, the primary pumping chamber of the heart, by 40 percent and reduced fibrosis, the hardening of the heart lining that impairs its ability to contract, by up to 50 percent. "This work demonstrates a novel non-invasive mesenchymal stem cell (MSC) therapeutic regimen for heart failure based on an intramuscular delivery route," said Techung Lee, Ph.D., UB associate professor of biochemistry and senior author on the paper. Mesenchymal stem cells are found in the bone marrow and can differentiate into a variety of cell types. "Injecting MSCs or factors released by MSCs improved ventricular function, promoted myocardial regeneration, lessened apoptosis (cell death) and fibrotic remodelling, recruited bone marrow progenitor cells and induced myocardial expression of multiple growth factor genes," Lee said. "These findings highlight the critical 'cross-talks' between the injected MSCs and host tissues, culminating in effective cardiac repair for the failing heart." The heart disease death rate has dropped significantly in the last three decades due to better treatments, resulting in large numbers of people living with heart failure. This advance has lead to another health hurdle: The only therapy available to reverse the decline in cardiac function is heart transplantation, and donor hearts are very scarce. Clinical trials of myocardial stem cell therapy traditionally have relied on surgery — infusing the stem cells directly into the heart or injecting them into the myocardium, the heart muscle — invasive methods that can result in harmful scar tissue, arrhythmia, calcification or small vessel blockages. "In our research with a swine model of heart failure," said Lee, "we've found that only 1-to-2 percent of MSCs infused into the myocardium grafted into the heart, and there was no evidence that they differentiated into heart muscle cells. In addition, diseased tissue is not a healthy environment for cell growth.” "For these reasons, and because patients with heart failure are not good surgical risks, it made sense to explore a non-invasive cell delivery approach," said Lee. An important feature of MSCs is their ability to produce a plethora of tissue healing effects, known as "trophic factors," which can be harnessed for stem cell therapy for heart failure. Lee noted that the multiple trophic factors produced by MSCs have been shown in the literature to be capable of reducing tissue injury, inhibiting fibrosis, promoting angiogenesis, stimulating recruitment and proliferation of tissue stem cells, and reducing inflammatory oxidative stress, a common cause of cardiovascular disease and heart failure. "Since skeletal muscle is the most abundant tissue in the body and can withstand repeated injection of large number of stem cells, we thought it would be a good method to deliver MSCs," Lee said. "We hypothesized that MSCs, via secretion of these functionally synergistic trophic factors, would be able to rescue the failing heart even when delivered away from the myocardium.” "This study proves our hypothesis," said Lee. "We've demonstrated that injecting MSCs, or trophic factors released by MSCs, into skeletal muscle improved ventricular function, promoted regeneration of heart tissue, decreased cell death and improved other factors that cause heart failure.” "This non-invasive stem cell administration regimen, if validated clinically, is expected to facilitate future stem cell therapy for heart failure." Lee said the next step is to use genetic and pharmacological engineering to make the stem cells more active, so good therapeutic effects can be achieved with fewer cells. "That is our goal. It would reduce the cost of stem cell therapy and make it more affordable for patients in the future." Reference: Heart Failure Therapy Mediated by the Trophic Activities of Bone Marrow Mesenchymal Stem Cells: A Non-invasive Therapeutic Regimen Arsalan Shabbir, David Zisa, Gen Suzuki, and Techung Lee Am J Physiol Heart Circ Physiol (April 24, 2009). doi:10.1152/ajpheart.00186.2009 ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Monday, 11 May 2009

Swine Flu I

What does it do to pigs? Monday, 11 May 2009 The effects of H1N1 swine flu have been investigated in a group of piglets. Scientists writing in BioMed Central's open access Virology Journal studied the pathology of the virus, finding that all infected animals showed flu-like symptoms between one and four days after infection and were shedding virus two days after infection. Roongroje Thanawongnuwech led a team of researchers from Chulalongkorn University, Bangkok, who infected 22-day old pigs with both the H1N1 strain of swine flu and the less dangerous H3N2 subtype. "The results demonstrated that both swine flu subtypes were able to induce flu-like symptoms and lung lesions in weanling pigs. However the severity of the disease with regard to both gross and microscopic lung lesions was greater in the H1N1-infected pigs", he said. All infected pigs developed respiratory symptoms such as nasal discharge, coughing, sneezing and conjunctivitis. Upon pathological examination, lung lesions large enough to be seen by the naked eye were observed. "These lesions were characterized by dark plum-coloured, consolidated areas on lung lobes and were most severe two days after infection, especially in the H1N1-infected pigs, where approximately a third of the lung was covered", according to Thanawongnuwech. The course of infection was limited to less than a week and none of the animals died. Reference: Pathogenesis of swine influenza virus (Thai isolates) in weanling pigs: an experimental trial Donruethai Sreta, Roongtham Kedkovid, Sophon Tuamsang, Pravina Kitikoon and Roongroje Thanawongnuwech Virology Journal 2009, 6:34 doi:10.1186/1743-422X-6-34 ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Thursday, 15 January 2009

Bone Marrow Stem Cells Regenerate Skin

New study suggests that adult bone marrow stem cells can be used in the construction of artificial skin Thursday, 15 January 2009 A new study suggests that adult bone marrow stem cells can be used in the construction of artificial skin. The findings mark an advancement in wound healing and may be used to pioneer a method of organ reconstruction. The study is published in Artificial Organs, official journal of the International Federation for Artificial Organs (IFAO), the The International Faculty for Artificial Organs (INFA) and the International Society for Rotary Blood Pumps (ISRBP). To investigate the practicability of repairing burn wounds with tissue-engineered skin combined with bone marrow stem cells, the study established a burn wound model in the skin of pigs, which is known to be anatomically and physiologically similar to human skin. Engineering technology and biomedical theory methods were used to make artificial skin with natural materials and bone marrow derived stem cells. Once the artificial skin was attached to the patient and the dermal layer had begun to regenerate, stem cells were differentiated into skin cells. The cells are self-renewing and raise the quality of healing in wound healing therapy. When grafted to the burn wounds, the engineered skin containing stem cells showed better healing, less wound contraction and better development of blood vessels. Skin, the human body's largest organ, protects the body from disease and physical damage, and helps to regulate body temperature. When the skin has been seriously damaged through disease or burns, the body often cannot act fast enough to repair them. Burn victims may die from infection and the loss of plasma. Skin grafts were originally developed as a way to prevent such consequences. "We hope that this so-called 'engineered structural tissue' will someday replace plastic and metal prostheses currently used to replace damaged joints and bones by suitable materials and stem cells," says Yan Jin of the Fourth Military Medical University, lead author of the study. Yan Jin is a chair professor and director of the Department of Oral Histology and Pathology of the School of Stomatology, and director of the Center of Tissue Engineering at the Fourth Military Medical University, Xian, China. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Thursday, 25 September 2008

Cloned Pigs with Cystic Fibrosis

Model to mimic human disease Thursday, 25 September 2008 In a first, researchers at the University of Iowa and the University of Missouri (MU) have developed a pig model for Cystic Fibrosis (CF) that appears to closely mimic the disease in human infants. The striking similarities between disease manifestations in the CF piglets and human newborns with CF suggest that this new model will help improve understanding of the disease and may also speed discovery of new treatments. The study is published in the Sept. 26 issue of Science. CF is a common hereditary disease that affects multiple organ systems, including the intestines, pancreas, and lung. Mice with CF-causing mutations have helped researchers learn more about this disease, however, differences in physiology and biology mean that mice with CF mutations do not develop many of the typical symptoms that affect humans with CF. Pig born with cystic fibrosis. Credit: University of Missouri Cystic Fibrosis (CF) continues to be a lethal disease for humans despite the identification of the problematic gene two decades ago. Many humans born with CF – the most common genetic disease in Caucasians - often die because of a lung disease developed later. Scientists have been unable to develop an animal model that develops the fatal lung disease. Now, a University of Missouri researcher is producing pigs born with cystic fibrosis that mimic the exact symptoms of a newborn with CF. The researchers are hopeful that these pigs will continue to mimic the human symptoms so the fatal lung disease can be studied and ultimately treated. "Right now, if you want to do experiments to find treatments or therapies for the lung disease that is fatal for people with CF, you would have to experiment on kids that have CF," said Randy Prather, distinguished professor of reproductive biotechnology in the MU College of Agriculture, Food and Natural Resources. "When the genetic mutation is introduced into mice, they do not display the symptoms of CF. That's why these new swine models are so important. We have been able to get them through the initial stages of the disease, which they display just like humans, and now we are just waiting for them to grow and potentially develop the lung disease so we can start experimenting in ways that have never been possible." Prather collaborated with Michael Welsh from the Howard Hughes Medical Institute at the University of Iowa. To create the genetic defect in pigs, a team led by Welsh made genetic modifications in pig cells. Prather's group then generated the genetically modified pigs from the cells using a process known as nuclear transfer. The pigs – called founder animals - that were produced carried only one copy of the mutated gene. Prather bred the pigs naturally and now many piglets have been born with CF. Once a litter is born, the piglets are immediately flown to Iowa where physicians who perform the corrective surgery on human newborns with CF do the same for the pigs. Meanwhile, MU researchers perform analysis during the transit to determine which piglets have the mutations "So far, all the mutations in the pigs have exactly mimicked the problems in humans born with CF," Prather said. "The whole cellular physiology of the pig is similar to humans. That's why having this break- through model is so exciting for the potential it has to move research on cystic fibrosis forward." "Lack of a better model has hampered our ability to answer long-standing questions in CF," explained Christopher Rogers, Ph.D., a former postdoctoral fellow in internal medicine at the UI Roy J. and Lucille A. Carver College of Medicine, and one of the study's lead authors. "The CF pig provides a unique opportunity to study one of the most common genetic diseases, and we hope to translate this new knowledge into better therapies and preventions." In addition to Rogers, co-lead authors of the study were David Stoltz, M.D., Ph.D., UI assistant professor of internal medicine, and David Meyerholz, D.V.M., Ph.D., UI assistant professor of pathology. The senior study author was Michael Welsh, M.D., UI professor of internal medicine and molecular physiology and biophysics, who holds the Roy J. Carver Chair of Internal Medicine and Physiology and Biophysics. Welsh also is a Howard Hughes Medical Institute investigator. CF occurs when a person inherits two mutated copies of the CFTR gene leading to loss of ion channel function that adversely affects many organs. To create the CF pigs, the researchers used gene targeting to disrupt one copy of the normal gene in pig cells. They then cloned these altered cells to produce pigs with only one good copy of the gene. Like human CF-carriers, these animals did not show disease symptoms. The pigs were then bred naturally, and about one in four of the piglets were born with two disrupted copies of the gene. The researchers established that piglets lacking CFTR have the abnormal ion channel activity that is a hallmark of CF disease. They also showed that the CF piglets develop the same disease characteristics that are commonly seen in newborn humans with CF, including a bowel obstruction known as meconium ileus, which often is the first sign of CF in humans. The pigs also have an abnormal pancreas, liver, and gall bladder, similar to CF patients. "Thus far, the clinical, physiological and age-related appearance of disease in the pigs, as well as the organs involved, mimic CF seen in people," Stoltz said. A primary cause of death and disability in patients with CF is lung disease. However, many questions remain about how infection and inflammation leads to lung damage. In the study, the lungs of the newborn CF pigs appeared similar to the lungs of their normal littermates and had no sign of infection or inflammation, possibly shedding some initial insight on the process. As the CF pigs mature and are exposed to airborne bacteria and viruses, the researchers hope to learn more about how and why lung disease develops in patients with CF. "Researchers can now begin to study the disease progression as it is happening, something not possible in humans," Meyerholz said. Reference: Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs Christopher S. Rogers, David A. Stoltz, David K. Meyerholz, Lynda S. Ostedgaard, Tatiana Rokhlina, Peter J. Taft, Mark P. Rogan, Alejandro A. Pezzulo, Philip H. Karp, Omar A. Itani, Amanda C. Kabel, Christine L. Wohlford-Lenane, Greg J. Davis, Robert A. Hanfland, Tony L. Smith, Melissa Samuel, David Wax, Clifton N. Murphy, August Rieke, Kristin Whitworth, Aliye Uc, Timothy D. Starner, Kim A. Brogden, Joel Shilyansky, Paul B. McCray, Jr., Joseph Zabner, Randall S. Prather, Michael J. Welsh Science 26 September 2008, Vol. 321. no. 5897, pp. 1837 – 1841, DOI: 10.1126/science.1163600 New Pig Model Could Improve Understanding of Cystic Fibrosis HHMI NEWS - September 26, 2008 ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Wednesday, 10 September 2008

hESCs Minimized Tissue Injury in Pigs

Lab studies, conducted by Singapore and the Netherlands scientists, show that stem cell secretions minimized tissue injury after heart attack. Wednesday, 10 September 2008 A novel way to improve survival and recovery rate after a heart attack was reported in the journal Stem Cell Research by scientists at Singapore's Institute of Medical Biology (IMB) and Bioprocessing Technology Institute (BTI) and The Netherlands' University Medical Center Utrecht. This method, developed in laboratory research with pigs, is the first non-cell based therapeutic application of human embryonic stem cells (hESCs). It entails using secretions from stem cells. In their studies with pigs, the researchers found that the administration of secretion from stem cells minimized heart injury by enhancing reperfusion therapy (angioplasty and cardiac bypass surgery) and reducing tissue death by another 60%. Heart function was also markedly improved, the scientists report in the paper, published in the June 2008 issue of the journal. By demonstrating the efficacy of this secretion in an experimental pig model, currently the best approximation to a human heart attack patient undergoing reperfusion therapy, the researchers say that they have addressed the longstanding problem of reperfusion injury in the most clinically relevant experimental setting. "Using secretion instead of cells allows us to circumvent many highly intractable problems such as tumour formation, immune compatibility, cell viability, delivery, costs and timeliness," said IMB'S Dr Sai-Kiang Lim, who leads the Singapore-The Netherlands collaboration. Unlike the more common approach of directly administering stem cells for therapy, this new method carries negligible risk of tumour formation or rejection by the body. In the pig research model, this approach minimised heart injury after a heart attack, a particularly important consideration since the heart has a limited ability to regenerate. The research was carried out on pigs because it is the closest animal approximation to the human heart in terms of size, structure and function. The findings are especially important as they show that the new method can overcome the unwanted side effects of reperfusion, currently the best therapeutic option available to heart attack patients. Reperfusion is the restoration of blood flow to the oxygen-deprived heart after a heart attack. "This is a major discovery of clinical significance. There are some problems and issues associated with the use of stem cells to treat heart attacks and blocked arteries in the heart, and with this new method, many of these issues are removed. Potentially, we may have an important way to treat heart attacks. More tests will need to be done and human trials planned," said advisor to the Singapore researchers, Lee Chuen-Neng, M.D., who heads National University Hospital of Singapore's Department of Cardiac, Thoracic and Vascular Surgery. He also is Chair of Surgery at the National University Health System. This discovery is all the more significant because the therapy for reperfusion injury remains an unmet need despite three decades of huge resource investment, thousands of research papers and hundreds of experimental protocols. This preclinical study had come amidst an international call to improve the translation of preclinical experimental therapies for reperfusion injury to clinical applications. Heart attack or myocardial infarction (MI), occurs when blood flow to part of the heart is blocked, and the heart muscle is deprived of oxygen. If allowed to persist, prolonged oxygen deprivation causes cell death and irreversible loss of heart function, and inevitably progresses to heart failure and death. To minimise heart muscle damage and preserve the pumping action of the heart after a MI, early reperfusion by standard medical treatments such as angioplasty (commonly known as "ballooning") or bypass surgery is carried out in the hospital. Despite this, most MI patients suffer additional irreversible cardiac muscle cell loss, ironically as a result of these treatments — a condition known as reperfusion injury. As Singapore moves from basic science towards translational studies in the next phase of its biomedical push, rigorous preclinical testing and carefully designed studies such as this project would be most critical in ensuring the success of clinical trials. Professor Birgit Lane, IMB's Executive Director, said: "This is a very exciting result from Dr. Lim and her colleagues. It paves the way for improved recovery after heart attack – a very practical outcome from stem cell research. It is a great example of what can be achieved when doctors and scientists work closely together. By sharing their specialist skills and knowledge, they can discover and refine new approaches to curing sick people. This targeting of research to find ways of combating illness and benefiting people faster is at the heart of what we aim to do at IMB." ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Tuesday, 1 July 2008

HFEA Licence Human-pig Hybrid Embryos

HFEA Licence Human-pig Hybrid Embryos 
Tuesday, 01 July 2008 

A licence to create human-pig embryos to study heart disease has been issued by the British fertility watchdog the Human Fertilisation and Embryology Authority. This is the third animal-human hybrid embryo licence to be issued by HFEA and the first since the Commons voted in favour of this controversial research last month. An HFEA spokesman said it had approved an application from the Clinical Sciences Research Institute, University of Warwick, for the creation of hybrid embryos. 

The centre has been offered a 12 month licence with effect from today, July 1. The Licence Committee was satisfied that the research was permissible within the law and met the criteria required by the 1990 Human Fertilisation and Embryology Act. 

The effort at the University of Warwick is led by Professor Justin St John

"This new license allows us to attempt to make human pig clones to produce embryonic stem cells," he said to The Telegraph. 

 He will study mutation for certain kinds of cardiomyopathies, which make the heart lose its pumping strength. He researchers will mainly study the power-houses of cells, the mitochondria, and genetic defects that affect their ability to support heart cells. 

 Teams in Newcastle and London are already creating hybrids. The former have already created hybrids with cow eggs to study the basics of how the use of genes changes in early development, the latter a range of species to generate stem cells from people with neurodegenerative disorders. 
......... 

ZenMaster


For more on stem cells and cloning, go to CellNEWS 
at http://cellnews-blog.blogspot.com/

Monday, 14 January 2008

Recreation of Beating Heart in the Laboratory

Method may revolutionize how heart and other organ tissues are developed Monday, 14 January 2008 University of Minnesota researchers have created a beating heart in the laboratory. By using a process called whole organ decellularization, scientists from the University of Minnesota Center for Cardiovascular Repair grew functioning heart tissue by taking dead rat and pig hearts and reseeding them with a mixture of live cells. The research will be published online in the January 13 issue of Nature Medicine. “The idea would be to develop transplantable blood vessels or whole organs that are made from your own cells,” said Doris Taylor, Ph.D., director of the Center for Cardiovascular Repair, Medtronic Bakken professor of medicine and physiology, and principal investigator of the research. Nearly 5 million people live with heart failure, and about 550,000 new cases are diagnosed each year in the United States. Approximately 50,000 United States patients die annually waiting for a donor heart. While there have been advances in generating heart tissue in the lab, creating an entire 3-dimensional scaffold that mimics the complex cardiac architecture and intricacies, has always been a mystery, Taylor said. It seems decellularization may be a solution – essentially using nature’s platform to create a bioartifical heart, she said. Decellularization is the process of removing all of the cells from an organ – in this case an animal cadaver heart – leaving only the extracellular matrix, the framework between the cells, intact. This was done by perfusing the heart with a solution of detergent. After successfully removing all of the cells from both rat and pig hearts, researchers injected them with a mixture of progenitor cells that came from neonatal or newborn rat hearts and placed the structure in a sterile setting in the lab to grow. The results were very promising, Taylor said. Four days after seeding the decellularized heart scaffolds with the heart cells, contractions were observed. Eight days later, the hearts were pumping. “Take a section of this ‘new heart’ and slice it, and cells are back in there,” Taylor said. “The cells have many of the markers we associate with the heart and seem to know how to behave like heart tissue.” “We just took nature’s own building blocks to build a new organ,” said Harald C. Ott, M.D., co-investigator of the study and a former research associate in the center for cardiovascular repair, who now works at Massachusetts General Hospital. “When we saw the first contractions we were speechless.” Researchers are optimistic this discovery could help increase the donor organ pool. In general, the supply of donor organs is limited and once a heart is transplanted, individuals face life-long immunosuppression, often trading heart failure for high blood pressure, diabetes, and kidney failure, Taylor said. Researchers hope that the decellularization process could be used to make new donor organs. Because a new heart could be filled with the recipient’s cells, researchers hypothesize it’s much less likely to be rejected by the body. And once placed in the recipient, in theory the heart would be nourished, regulated, and regenerated similar to the heart that it replaced. “We used immature heart cells in this version, as a proof of concept. We pretty much figured heart cells in a heart matrix had to work,” Taylor said. “Going forward, our goal is to use a patient’s stem cells to build a new heart.” Although heart repair was the first goal during research, decellularization shows promising potential to change how scientists think about engineering organs, Taylor said. “It opens a door to this notion that you can make any organ: kidney, liver, lung, pancreas – you name it and we hope we can make it,” she said. Reference: Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart Harald C Ott, Thomas S Matthiesen, Saik-Kia Goh, Lauren D Black, Stefan M Kren, Theoden I Netoff & Doris A Taylor Published online: 13 January 2008; doi:10.1038/nm1684 ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://www.geocities.com/giantfideli/index.html

Friday, 19 October 2007

Xenotransplanting embryonic pig pancreatic cells

Cross-species transplant in rhesus macaques is step toward diabetes cure for humans Friday, 19 October 2007 With an eye on curing diabetes, scientists at Washington University School of Medicine in St. Louis have successfully transplanted embryonic pig pancreatic cells destined to produce insulin into diabetic macaque monkeys – all without the need for risky immune suppression drugs that prevent rejection. The transplanted cells, known as primordia, are in the earliest stages of developing into pancreatic tissues. Within several weeks of the transplants, the cells became engrafted, or established, within the three rhesus macaque monkeys that received them. The cells also released pig insulin in response to rising blood glucose levels, as would be expected in healthy animals and humans. "The approach reduced the animals' need for insulin injections and has promise for curing diabetes in humans," says senior investigator Marc Hammerman, M.D., the Chromalloy Professor of Renal Diseases in Medicine. "The transplants worked without a need for immune suppression and that is a major obstacle we have overcome." Although the transplants fell short of producing sufficient insulin to cure the macaques' diabetes, Hammerman predicts that with additional research, including the transplantation of additional embryonic pig cells into the animals, he will be able to reduce their need for insulin injections entirely. The new research follows on the heels of reports by Hammerman and his colleagues demonstrating that transplanted pig pancreatic primordia can cure both type 1 and type 2 diabetes in rats, without using immune suppression drugs. Other scientists have tried different types of pancreatic cell transplants – in animals and humans – as a stepping stone to curing diabetes, but they all require anti-rejection drugs. These drugs must be taken daily to stave off rejection and have adverse effects of their own that limit the success of the transplants. As a treatment for diabetes in people, pig insulin typically works as well as the human form. Before recombinant DNA technology enabled pharmaceutical companies to manufacture human insulin in the 1980s, pig and cow insulin were routinely given to diabetic patients. The primates in the current study had type 1 diabetes, the form that occurs when islet cells in the pancreas stop producing insulin all together. The Washington University researchers transplanted 19 embryonic pig pancreatic primordia into each diabetic monkey. Each primordia is smaller than the diameter of a period that ends a sentence and is transplanted into a membrane that envelops the intestines and other digestive organs. The transplanted cells were retrieved from the pig embryos early in their development, which is believed to render them "invisible" to the primates' immune system or induce a state of tolerance, either of which eliminates the need for immune suppression. The researchers determined by multiple methods that the transplanted cells became established within the primates. And as the cells matured, they began to release pig insulin. "We found using every method that the cells engraft long-term and, thus, are not rejected by the animals' immune systems," Hammerman says. "It's been more than two years since our first transplant was carried out. That particular primate doesn't produce any primate insulin, but has pig insulin circulating in its bloodstream that has reduced by more than 50 percent the amount of injected insulin the animal needs, compared to levels before the transplant. The animals have never received immune suppression drugs." Two of the macaques remain healthy. One, however, became anaemic about six weeks post-transplant and was euthanized a month later after developing acute respiratory distress. The researchers could not find a link between this animal's illness and the pancreatic cell transplants. The two remaining macaques have each received two transplants of embryonic pancreatic cells. One of the animals has been followed for 23 months after his first transplant, and the amount of insulin he needs to have injected has declined by some 55 percent over baseline levels. The other macaque has been followed for 10 months after his initial transplant, and his need for injected insulin continues to decline over time. Hammerman and his colleague Sharon Rogers, research instructor in medicine, are leaders in the emerging field of organogenesis, which focuses on growing organs from transplanted embryonic organ precursors known as primordia. Unlike embryonic stem cells, which can become virtually any cell type, primordia are locked into becoming cells of a particular organ. "We are encouraged by these results," Rogers says. "The absence of a need for immune suppression in diabetic rats gave us hope that we were on the right track. But many findings in rats do not hold true for species that are more closely related to humans, such as non-human primates. This one did." The team will now determine how best to eliminate the need for injected insulin in the diabetic macaques that receive transplants, thus demonstrating long-term effectiveness of the technique, and establish the absolute safety of pancreatic primordia transplants. If these experiments succeed, the researchers plan to conduct clinical trials in humans with diabetes. "We hope to find out how to apply our findings to human type 1 and type 2 diabetics because the embryonic pig primordia would represent an unlimited source of tissue for transplantation," Hammerman says. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://www.geocities.com/giantfideli/index.html

Sunday, 29 July 2007

Would you like a pig’s heart?

Is it right to clone animals for human transplants? July 29, 2007 Several research groups, and companies, are trying to make transgenic and cloned pigs to alleviate the organ donor shortage. Opponents have said that it raises serious ethical issues over the use of animals and poses a major safety question for humans. Do you think this marks a scientific breakthrough in cloning and availability of organs for transplants? Or does it raise concerns over the methods being used in cloning technology? Could you think of receiving a pig organ or tissue yourself, if needed? Pigs are very suitable for many reasons, they haven’t been chosen without thought: they are about the same size (body weight) as we are, they have a very similar internal anatomy as we, they grown fast (full size within a year) and are genetically well characterised. Several research groups, and now companies, are trying to make transgenic pigs for many years now, which would lack one of the major immunological obstacles to this xenotransplantation (transplanting organs between different animals and humans). It’s a simple sugar molecule on the surface of pig cells that now has been removed in these new breeds, and before was known to be the major immunological reactant in humans transplanted with pig tissues. The animals lack the gene responsible for "alpha-1,3-galactosyltransferase" (GT) — an enzyme normally present in the pig vascular system. Humans have natural, preformed antibodies to GT, resulting in immediate (acute) rejection of any pig-to-human transplant. The fact that these genetically engineered "GT-knockout" pigs lack GT removes one obstacle to cross-species transplantation, or xenotransplantation, between pigs and humans. Apart from the possible transplantation of organs such as the kidney or heart, pigs are also viewed as a potentially invaluable source of islet cells — the insulin-producing cells of the pancreas — for use in transplantation as a treatment for type-1 diabetes. Preliminary studies have reported encouraging results with transplantation of organs from GT-KO pigs into nonhuman primates. Hearts transplanted from GT-KO pigs into baboons have survived for several months, without the need for intensive drug treatment to suppress the recipient animal's immune system. However, many obstacles remain to be overcome before exploratory studies of xenotransplantation from GT-KO pigs to humans can begin. The transplanted hearts do not show the pattern of acute, overwhelming rejection typical of cross-species transplantation. However, there is evidence of another type of rejection, characterized by blood clots developing in the small blood vessels. This suggests a possible "coagulation dysregulation" between pigs and primates. New approaches will be needed to address the problem: either improved approaches to immunosuppressant drug therapy or further genetic manipulation of the donor animals. A lot is also known about pig’s physiology during medical procedure’s which make them suitable for this kind of treatment. Do you know that live sedated pigs are used for many training purposes for catastrophe medicine (surgeons who need training on complex wounds) and military doctors (shot gun and shell wounds)! Some argue these issues can be very emotional and scary for many people. True, but that’s exactly why they need to be discussed, to take away the scary part. It is usually when you don’t know, or don’t talk about something straight out, it becomes more and more scary. When you get to know the details and ventilating your anxiety it usually becomes easier to live with. Some people ask “Why spend so much money and effort on this?” This kind of work to develop donor organs from pigs, is not particular expensive compared to other things our societies put money on. And in the long run there will be a lot of savings instead, when people can live a healthy life instead. And they are definitely not impractical experiments. If you think so, you have not understood the slightest of what can be done to help people. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://www.geocities.com/giantfideli/index.html